John Maher | CSO
Leucid Bio

John Maher, CSO, Leucid Bio

Dr John Maher is a clinical immunologist and immunopathologist who leads the "CAR Mechanics" research group within King's College London. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells. He is also chief scientific officer of a spin-out company named Leucid Bio. In addition, he is a consultant immunologist within King's Health Partners and Eastbourne Hospital.


Day 1: Wednesday 19th May 2021 - Cell Therapy @ 14:00

Gamma delta T-Cells: Potential off the shelf treatment for solid tumours

·Circulating gamma delta T-cells expand more efficiently in the presence of TGF beta·These cells also exhibit superior fitness and resistance to cell death·TGFb supplemented gamma delta T-cells display enhanced anti-tumour activity, either when unmodified or genetically targeted using a CAR

Day 1: Wednesday 19th May 2021 - Cell Therapy @ 15:30

Panel: Tackling solid tumours

·Hurdles to solid tumour cell therapy and novel strategies to overcome·Autologous and allogeneic cell therapy for solid tumours·Potential role for combination cellular therapies
last published: 10/May/21 08:45 GMT

back to speakers